Intriguingly, knock-down of IKZF1 sensitizes tumor cells in DLBCL to treatment with the EZH2 inhibitor tazemetostat [35], not only emphasizing its biological, but also a possible clinical impact in lymphoma. The gene discussed is EZH2; the disease is neoplasm.